MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.17936

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2024

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.

Ricciuto Amanda, Liu Kuan, El-Matary Wael, Amin Mansi, Amir Achiya Z, Aumar Madeleine, Auth Marcus, Di Guglielmo Matthew D, Druve Tavares Fagundes Eleonora, Rodrigues Ferreira Alexandre, Furuya Katryn N, Gupta Nitika, Guthery Stephen, Horslen Simon P, Jensen Kyle, Kamath Binita M, Kerkar Nanda, Koot B G P, Laborda Trevor J, Lee Christine K, Loomes Kathleen M, Mack Cara, Martinez Mercedes, Montano-Loza Aldo, Ovchinsky Nadia, Papadopoulou Alexandra, Perito Emily R, Sathya Pushpa, Schwarz Kathleen B, Shah Uzma, Shteyer Eyal, Soufi Nisreen, Stevens James Patrick, Taylor Amy, Tessier M Elizabeth, Valentino Pamela, Woynarowski Marek, Deneau Mark, Pediatric PSC Consortium

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

BACKGROUND

Data on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited.

AIMS: Using data from the Paediatric PSC Consortium, to examine the effect of vancomycin on IBD activity.

METHODS

In this retrospective multi-centre cohort study, we matched vancomycin-treated and untreated patients (1:3) based on IBD duration at the time of primary outcome assessment. The primary outcome was Physician Global Assessment (PGA) of IBD clinical activity after 1 year (±6 months) of vancomycin. We used generalised estimating equations (GEE) to examine the association between vancomycin and PGA remission, adjusting for IBD type, severity and medication exposures. Secondary outcomes included serum labs and endoscopic remission (global rating of no activity) among those with available data and also analysed with GEE.

RESULTS

113 PSC-IBD patients received vancomycin (median age 12.7 years, 63% male). The matched cohort included 70 vancomycin-treated and 210 untreated patients. Vancomycin was associated with greater odds of IBD clinical remission (odds ratio [OR] 3.52, 95% CI 1.97-6.31; adjusted OR [aOR] 5.24, 95% CI 2.68-10.22). Benefit was maintained in sensitivity analyses restricted to non-transplanted patients and those with baseline moderate-severe PGA. Vancomycin was associated with increased odds of endoscopic remission (aOR 2.76, 95% CI 1.002-7.62; N = 101 with data), and with lower CRP (p = 0.03) and higher haemoglobin and albumin (both p < 0.01).

CONCLUSION

Vancomycin was associated with greater odds of IBD clinical and endoscopic remission. Additional, preferably randomised, controlled studies are needed to characterise efficacy using objective markers of mucosal inflammation, and to examine safety and define optimal dosing.

Для цитирования: Ricciuto Amanda, Liu Kuan, El-Matary Wael, Amin Mansi, Amir Achiya Z, Aumar Madeleine, Auth Marcus, Di Guglielmo Matthew D, Druve Tavares Fagundes Eleonora, Rodrigues Ferreira Alexandre, Furuya Katryn N, Gupta Nitika, Guthery Stephen, Horslen Simon P, Jensen Kyle, Kamath Binita M, Kerkar Nanda, Koot B G P, Laborda Trevor J, Lee Christine K, Loomes Kathleen M, Mack Cara, Martinez Mercedes, Montano-Loza Aldo, Ovchinsky Nadia, Papadopoulou Alexandra, Perito Emily R, Sathya Pushpa, Schwarz Kathleen B, Shah Uzma, Shteyer Eyal, Soufi Nisreen, Stevens James Patrick, Taylor Amy, Tessier M Elizabeth, Valentino Pamela, Woynarowski Marek, Deneau Mark, Pediatric PSC Consortium. Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.. Alimentary pharmacology & therapeutics. 2024. DOI: 10.1111/apt.17936.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.